Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have received an average recommendation of “Hold” from the sixteen brokerages that are presently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $17.35.

A number of equities research analysts have recently issued reports on the stock. BTIG Research set a $19.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, February 14th. ValuEngine raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. BidaskClub lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, February 25th. GMP Securities raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “neutral” rating and upped their price objective for the company from $11.50 to $14.00 in a report on Monday, February 25th. Finally, Wood & Company started coverage on shares of Ironwood Pharmaceuticals in a report on Tuesday, February 26th. They issued a “buy” rating for the company.

Shares of Ironwood Pharmaceuticals stock traded down $0.08 during trading hours on Wednesday, reaching $11.40. 1,057,209 shares of the company’s stock were exchanged, compared to its average volume of 1,491,030. Ironwood Pharmaceuticals has a 1 year low of $9.07 and a 1 year high of $21.20. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -12.00 and a beta of 1.91.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Wednesday, February 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.15. The business had revenue of $130.70 million for the quarter, compared to analysts’ expectations of $96.57 million. During the same period in the previous year, the company earned ($0.14) EPS. Ironwood Pharmaceuticals’s quarterly revenue was up 38.7% compared to the same quarter last year. As a group, equities analysts expect that Ironwood Pharmaceuticals will post 0.04 EPS for the current fiscal year.

In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 30,000 shares of the stock in a transaction dated Wednesday, January 23rd. The shares were sold at an average price of $12.66, for a total transaction of $379,800.00. Following the completion of the transaction, the chief executive officer now owns 4,726,917 shares of the company’s stock, valued at $59,842,769.22. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Peter M. Hecht sold 89,551 shares of the stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $12.53, for a total transaction of $1,122,074.03. Following the sale, the chief executive officer now directly owns 4,726,917 shares in the company, valued at approximately $59,228,270.01. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 403,872 shares of company stock valued at $5,281,958. 7.63% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth about $31,000. First Manhattan Co. acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth about $133,000. Gotham Asset Management LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth about $135,000. Bank of Montreal Can lifted its position in shares of Ironwood Pharmaceuticals by 426.9% during the fourth quarter. Bank of Montreal Can now owns 16,846 shares of the biotechnology company’s stock worth $175,000 after purchasing an additional 13,649 shares in the last quarter. Finally, Pacer Advisors Inc. acquired a new stake in shares of Ironwood Pharmaceuticals during the third quarter worth about $177,000. 97.00% of the stock is currently owned by institutional investors and hedge funds.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Recommended Story: What are municipal bonds?

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.